Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Halozyme ( (HALO) ) has issued an update.
On September 30, 2025, Halozyme Therapeutics, Inc. announced a merger agreement with Elektrofi, Inc., where Elektrofi will become a wholly-owned subsidiary of Halozyme. The deal involves an upfront payment of $750 million and potential milestone payments, with the merger subject to customary conditions and regulatory approvals.
The most recent analyst rating on (HALO) stock is a Buy with a $90.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.
Spark’s Take on HALO Stock
According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.
Halozyme’s strong financial performance and positive earnings call sentiment are the primary drivers of its high score. The technical analysis indicates strong momentum, although caution is advised due to overbought signals. The valuation is reasonable, supporting the overall positive outlook.
To see Spark’s full report on HALO stock, click here.
More about Halozyme
Halozyme Therapeutics, Inc. operates in the biotechnology industry, focusing on developing and commercializing products that enhance the delivery of biologics. The company is known for its proprietary enzyme technology, which is used to facilitate the subcutaneous administration of drugs.
Average Trading Volume: 1,939,218
Technical Sentiment Signal: Buy
Current Market Cap: $8.39B
Find detailed analytics on HALO stock on TipRanks’ Stock Analysis page.